Executive Director, US Medical Affairs (USMA) Strategy – Liver and Covid
The Executive Director (ED) USMA Strategy – Liver and Covid is a key member of the USMA leadership team, reporting to the VP of USMA, Virology, and office-based in Foster City, CA. This role is responsible for developing and driving the USMA strategies and respective medical annual plannings for Viral Hepatitis, Primary Biliary Cholangitis (PBC) and Covid-19 and provide representation in cross-functional HBV, HCV, HDV, PBC and COVID-19 working groups. The ED will oversee, develop, and maintain the tenor of Gilead's US scientific communications related to Viral Hepatitis, PBC and COVID-19 with the community of US health care professionals and advocates, ensuring high-quality deliverables such as medical affairs resources, medical presentations at conferences, advisory boards and medical engagements with US providers and advocates. Experience with launch planning and external collaborations will also be essential.
The salary range for this position is: $341,190.00 - $441,540.00. Gilead considers a variety of factors when determining base compensation, including experience, qualifications, and geographic location. This position may also be eligible for a discretionary annual bonus, discretionary stock-based long-term incentives (eligibility may vary based on role), paid time off, and a benefits package.
For additional benefits information, visit: Benefits Information
#J-18808-Ljbffr